I'm LongbridgeAI, I can summarize articles.Zoom pre-market up 7.49%; Haoxin pre-market down 7.41%; PicoCELA pre-market up 210.22%; Akari Therapeutics pre-market up 82.88%; MetaVia pre-market up 66.57%
Pre-market Hot Trades in US Stocks
Zoom is up 7.49% in pre-market trading. Based on recent key news:
-
On May 22, Zoom released an earnings report for the first quarter that exceeded expectations, with corporate revenue growing 7.2% year-over-year to $755.7 million, driving the stock price up. The company expects adjusted earnings per share for the second quarter to be between $1.45 and $1.47, with revenue potentially reaching $1.27 billion. Source: WSJ
-
On May 22, Zoom raised its full-year revenue and profit expectations, forecasting full-year revenue of $5.08 billion to $5.09 billion, with adjusted earnings per share of $5.96 to $6, exceeding market expectations. Source: Benzinga
-
On May 22, analysts generally raised Zoom's target price, with the average target price increasing from $98.65 to $103.48, reflecting market confidence in Zoom's future performance. Source: FactSet. Zoom's AI tool user growth is significant, and its performance in the enterprise market is strong.
Haoxin is down 7.41% in pre-market trading, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Top Gainers in Pre-market US Stocks
PicoCELA is up 210.22% in pre-market trading, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Akari Therapeutics is up 82.88% in pre-market trading. Based on recent key news:
-
On May 21, Akari Therapeutics announced the completion of a $5 million private placement, driving the stock price up. This move strengthens the company's financial position and attracts investor attention.
-
On May 22, the company implemented a 1-for-40 reverse stock split, resulting in a significant pre-market price increase of 105.58%. This move aims to enhance stock price stability and improve market confidence in the company's shares.
-
On May 22, Akari's AKTX-101 showed significant cytotoxic effects in cancer models when combined with KRAS inhibitors, enhancing market optimism about its R&D prospects. The biotechnology industry has been volatile recently and requires attention.
MetaVia is up 66.57% in pre-market trading. Based on recent key news:
-
On May 20, MetaVia Inc. released an important announcement via PR Newswire, potentially involving adjustments to the company's future development strategy or new product launches, leading to increased market optimism about its prospects and driving the stock price up significantly.
-
On May 22, MetaVia's stock price fell 3.63% during the trading session, closing at $2.78. According to data from Benzinga Pro, the market momentum indicator RSI reached 80.57, indicating an overbought condition that may trigger a short-term pullback
-
Recently, the key resistance level for MetaVia is $2.85, and the support level is $2.52. Technical factors may impact stock price fluctuations. Market momentum is strong, and caution is needed regarding short-term pullback risks